Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALTORL laryngeal preservation trial
2024-513976-16-00Phase 3Authorised
- Sponsor
- GORTEC
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel, cisplatin and fluorouracil in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx (2 arms), sponsored by GORTEC. Primary endpoint: Survival with preservation of laryngeal and pharyngoesophageal function. Planned start Jul 2024; status: authorised.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2024-513976-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513976-16-00.